Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common stomach bug raise your heart disease risk?

NCT ID NCT07306377

Knowledge-focused Sponsor: Tanta University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looked at 300 people to see if a common stomach infection, H. pylori, is linked to unhealthy blood fat levels that can lead to heart disease. Researchers measured triglycerides and 'good' cholesterol to calculate a heart risk score. The goal is to understand if treating this infection could also help protect the heart.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If a link is found, it could point to H. pylori infection as a new risk factor for heart disease, opening up potential prevention strategies.
What could go wrong
This is an observational study, so it cannot prove cause and effect. The results may not apply to everyone, and other factors could explain any link found.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

300 people

The number who actually took part.

Started

Jan 2025

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients (≥18 years) attending the Gastroenterology Unit at Tanta University Hospitals (Egypt) and the Internal Medicine Department at Tadawi Hospital (Saudi Arabia). Participants will include both men and women diagnosed with or without H. pylori infection, recruited consecutively during routine clinical visits.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients older than 18 years. * Able to sign the written consent. * Willing to participate in the research and undergo H. pylori testing. Exclusion criteria * Unwilling to participate in the study. * History of severe metabolic disorders. * Taking medications that affect adipose tissue metabolism. * History of gastric surgery.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atherogenic plasma index are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Helicobacter pylori infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atherogenic plasma index H.pylori infection

Contacts and locations

Locations

  • Faculty of Medicine

    Tanta, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.